文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

依沃西单抗联合化疗用于EGFR突变非小细胞肺癌的HARMONi-A随机临床试验最终总生存结果

Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR-Variant Non-Small Cell Lung Cancer: The HARMONi-A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2026-01-01

HARMONi-A是一项在中国55个中心开展的随机双盲安慰剂对照3期试验,纳入322例既往EGFR-TKI治疗后进展的EGFR突变非鳞状NSCLC成人患者。最终分析显示,依沃西单抗联合化疗较单纯化疗显著改善总生存(中位16.8 vs 14.1个月;分层HR 0.74;95%CI 0.58-0.95;

要点

  • 依沃西单抗联合化疗使中位总生存延长2.7个月(16.8 vs 14.1个月),HR 0.74。
  • 30个月生存率依沃西单抗组29.1%,安慰剂组18.4%。
  • ≥3级治疗中出现不良事件发生率依沃西单抗组67.1%,安慰剂组54.7%。

核心结论

  • 在既往EGFR-TKI治疗后进展的EGFR突变非鳞状NSCLC患者中,依沃西单抗联合化疗较单纯化疗显著改善总生存,且安全性可接受。

研究设计与样本

  • 患者按1:1随机接受依沃西单抗20 mg/kg(n=161)或安慰剂(n=161)联合培美曲塞和卡铂,每3周一次共4周期,后续维持治疗。
  • 主要终点为独立影像评审委员会评估的无进展生存期,本报告聚焦关键次要终点总生存,采用分层检验;数据截止日期2025年4月12日。

主要发现

  • 中位总生存绝对差异为2.7个月。
  • 估计30个月生存率依沃西单抗组29.1%(95%CI 22.1%-36.4%),安慰剂组18.4%(95%CI 12.8%-24.8%)。
  • ≥3级治疗中出现不良事件发生率依沃西单抗组67.1%,安慰剂组54.7%。
  • 患者中位年龄59.4岁,女性占51.6%。

临床怎么用

  • 对于既往EGFR-TKI治疗后进展的EGFR突变非鳞状NSCLC患者,可考虑依沃西单抗联合培美曲塞和卡铂方案。
  • 治疗期间需关注≥3级治疗中出现不良事件,依沃西单抗组发生率高于安慰剂组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Patients with epidermal growth factor receptor (EGFR) gene variant nonsquamous non-small cell lung cancer (NSCLC) who have disease progression after prior EGFR tyrosine kinase inhibitor (TKI) therapy have limited treatment options, creating a need for more effective subsequent therapies. OBJECTIVE: To provide final overall results of a trial assessing whether adding ivonescimab (a bispecific antibody targeting programmed cell death protein 1 and vascular endothelial growth factor) to chemotherapy improves overall survival in this population. DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind, placebo-controlled phase 3 trial conducted at 55 sites in China. From January 25 to November 2, 2022, a total of 322 adult patients with locally advanced or metastatic EGFR-variant nonsquamous NSCLC who had received prior EGFR-TKI therapy were enrolled. The data cutoff date was April 12, 2025. INTERVENTIONS: Patients were randomized 1:1 to receive ivonescimab (20 mg/kg; n = 161) or placebo (n = 161) plus chemotherapy with pemetrexed and carboplatin once every 3 weeks for 4 cycles, followed by maintenance therapy. MAIN OUTCOMES AND MEASURES: This final results report focuses on overall survival, the key secondary end point, tested in a hierarchical manner (the primary end point was progression-free survival assessed by an independent radiology review committee). RESULTS: The 322 enrolled patients had a median age of 59.4 years, and 51.6% were female. During a median follow-up of 32.5 months, ivonescimab plus chemotherapy improved overall survival compared with chemotherapy alone (median survival, 16.8 months vs 14.1 months; stratified hazard ratio, 0.74; 95% CI, 0.58-0.95; P = .02). The absolute difference in median overall survival was 2.7 months. Estimated 30-month survival rates were 29.1% (95% CI, 22.1%-36.4%) with ivonescimab and 18.4% (95% CI, 12.8%-24.8%) with placebo. Grade 3 or higher treatment-emergent adverse events occurred in 67.1% and 54.7% of patients receiving ivonescimab and placebo, respectively. CONCLUSIONS AND RELEVANCE: Ivonescimab plus chemotherapy provided a statistically significant and clinically meaningful improvement in overall survival with an acceptable safety profile in patients with EGFR-variant NSCLC after EGFR-TKI therapy. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05184712.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Fang W, Zhao Y, Luo Y, et al. Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR-Variant Non-Small Cell Lung Cancer: The HARMONi-A Randomized Clinical Trial. JAMA. 2026. PMID: 42307937. doi:10.1001/jama.2026.7745

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。